XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2

Interests in subsidiaries

12 Months Ended

Jun. 30, 2022

Investments accounted for using equity method [abstract]

Interests in subsidiaries

Note 30. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

				Ownership interest
Name		Principal place of business / Country of incorporation		2022 %				2021 %
Kazia Laboratories Pty Ltd		Australia			100.00	%			100.00	%
Kazia Research Pty Ltd		Australia			100.00	%			100.00	%
Kazia Therapeutics Inc.		United States of America			100.00	%			100.00	%
Glioblast Pty Ltd		Australia			100.00	%			100.00	%
Kazia Therapeutics (Hong Kong) Limited		Hong Kong			100.00	%			100.00	%

X

- Definition

The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph 2
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_2_b_i&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration